LDLRAD4 (Low Density Lipoprotein Receptor Class A Domain Containing 4)

These findings collectively identify LDLRAD4 as a promising therapeutic target for MDS. However, its clinical applicability warrants further investigation to validate its potential.

Furthermore, the expression of NUPR1 (encoding nuclear protein 1, transcriptional regulator), LDLRAD4 (encoding low density lipoprotein receptor class A domain containing 4) and MDM2 (encoding mouse double min 2) were verified by RT‑qPCR. Overall, the present study contributes to the understanding of the carcinogenic role of WSB2 in different types of cancer.

Our data further suggest that the loss of STK11 may function as a metabolic switch, suppressing lipid metabolism in favor of glycolysis, thereby negating KRAS-induced immunogenicity. Hence, this concept warrants continued exploration, both as a predictive biomarker and potential target for therapy in patients receiving ICI-based immunotherapy.

In summary, the proposed framework uncovers a set of clinically effective biomarkers that accurately classify NSCLC. As a future course of work, efforts would be made to combine a variety of omics data with histopathological data to unveil more precise biomarkers for devising personalized therapy.

Half of the patients (50%) received ICI monotherapy, whilst the other half had chemotherapy-ICI combination, 1 patient received Nivolumab-ipilimumab combination...Pembrolizumab (75%), Atezolizumab (12%) and Nivolumab (7%) were the most common ICIs prescribed... This GWAS pharmacogenomic study identified 7 novel variants in 4 genes associated with ICI response in advanced NSCLC. Current efforts are ongoing through validation in an independent patient cohort. These unique gene signatures, when validated and confirmed, may prove to be valuable tools in predicting ICI response in patients with advanced NSCLC.